Insulin therapy, delivered via subcutaneous (SC) injections or continuous subcutaneous insulin infusion (CSII) systems, remains indispensable, particularly in individuals with T1DM and those with progressive or inadequately controlled T2DM
As a GIP/GLP-1 receptor agonist, tirzepatide enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying
Thus, all clinicians prescribing GLP-1s for obesity management should establish a thoughtful plan of care that includes thorough nutritional and lifestyle counseling before, during, and after the weight reduction period
A large systemic review of cardiovascular outcomes of people taking GLP-1 agonists significantly reduces death from cardiovascular causes by 12% and stroke by 16%
Rates by dose, GLP-1 + glucagon mechanism, week-by-week timeline, and 8 management strategies
Now people think these are vanity drugs